Put MBHS on watch. The companys latest update was about what stage there SkinScan 650 is at and how physicians can do this test right in there offices. Were going to see some big things from this company in the near future, Stock has been showing some good volume and decent gains these past couple of days. Today hasnt done much but I think its ready for some big news soon!! I think were at a good entry price here @.25 We have seen thisat .38 a few weeks ago and when news hits the wire I think we will be trading at that level again or even higher. I think were at a good entry price here. Here is the latest news from 7/16 there is also a link to the webite in the news. Check it out..
TEL AVIV, Israel, July 16, 2010 (GLOBE NEWSWIRE) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS - News) today issued a stockholder update. The Company believes in the importance of regular communication and timely information delivered to investors. To this end, MBHS is committed to share with its stockholders regular updates on its progress.
MBHS, through its wholly owned subsidiary Skin Cancer Scanning ltd. ("SCS") is pioneering the development and commercialization of a revolutionary and proprietary diagnostic device for the early detection and diagnosis of skin cancer. Our product, an advanced stage prototype, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers.
SkinScan 650's state-of-the-art technology will enable physicians to improve their diagnostic abilities using SkinScan 650. This will replace current diagnostic procedures that have many disadvantages, such as being relatively subjective and dependent on the experience of the examiner. Errors in diagnosis can be fatal. Cancers can remain undetected, grow further and lower chances of survival. A biopsy, the intrusive removal of tissue sample, is usually needed for further diagnoses.
To date, we have successfully conducted two stages of clinical trials. The results from 128 scanned nevi demonstrated 92.4% accuracy in diagnosing non-melanoma skin cancer. These results are significantly higher than the 75% accuracy achieved by an experienced physician and 65% accuracy achieved by a general practitioner.